Summit updates on Phase 1b trial for SMTC1100 | 21 May 2014 | Stock Market Wire: "StockMarketWire.com - Summit Corporation says SMT C1100 for the treatment of Duchenne Muscular Dystrophy (DMD) has successfully met its primary endpoint of safety and tolerability in a Phase 1b clinical trial in patients with the disease.
SMT C1100 is an oral small molecule utrophin modulator that has the potential to treat all patients with DMD, regardless of the underlying dystrophin fault causing the disease.
The Phase 1b dose-escalating trial was conducted in 12 patients with DMD aged between 5 and 11 years old.
"These preliminary results show that SMT C1100 was safe and well tolerated at all doses tested in the study, and that there were no issues with patient compliance," Summit said. "
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment